ITRM Stock Forecast 2025-2026
Distance to ITRM Price Targets
ITRM Price Momentum
10 Quality Stocks Worth Considering Now
Researching Iterum Therapeutics (ITRM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on ITRM and similar high-potential opportunities.
Latest ITRM Stock Price Targets & Analyst Predictions
Based on our analysis of 5 Wall Street analysts, ITRM has a bullish consensus with a median price target of $7.50 (ranging from $5.00 to $10.00). Currently trading at $1.33, the median forecast implies a 463.9% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Gregory Renza at RBC Capital, projecting a 651.9% upside. Conversely, the most conservative target is provided by Ed Arce at HC Wainwright & Co., suggesting a 275.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ITRM Analyst Ratings
ITRM Price Target Range
Latest ITRM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ITRM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 10, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $5.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Maintains | $5.00 |
| Jun 21, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| May 31, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| May 14, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Apr 30, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Apr 1, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Mar 6, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Reiterates | $6.00 |
| Feb 7, 2024 | HC Wainwright & Co. | Ed Arce | Buy | Upgrade | $6.00 |
| Jul 27, 2021 | Gabelli & Co. | Kevin Kedra | Hold | Upgrade | $0.00 |
| Jul 26, 2021 | HC Wainwright & Co. | Ed Arce | Neutral | Downgrade | $0.00 |
| May 28, 2021 | Gabelli & Co. | Hold | Upgrade | $0.00 | |
| Mar 15, 2021 | HC Wainwright & Co. | Buy | Upgrade | $0.00 | |
| Oct 1, 2020 | SVB Leerink | Ami Fadia | Market Perform | Maintains | $1.50 |
| Jun 16, 2020 | HC Wainwright & Co. | Neutral | Downgrade | $0.00 | |
| Jun 2, 2020 | SVB Leerink | Market Perform | Maintains | $1.00 | |
| Jun 2, 2020 | RBC Capital | Sector Perform | Downgrade | $2.00 | |
| Dec 11, 2019 | RBC Capital | Gregory Renza | Outperform | Maintains | $10.00 |
| Dec 11, 2019 | SVB Leerink | Ami Fadia | Market Perform | Downgrade | $4.00 |
| Jun 21, 2019 | H.C. Wainwright | Buy | Initiates | $0.00 |
Iterum Therapeutics plc (ITRM) Competitors
The following stocks are similar to Iterum Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Iterum Therapeutics plc (ITRM) Financial Data
Iterum Therapeutics plc has a market capitalization of $45.99M with a P/E ratio of 0.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of +607.1%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Iterum Therapeutics plc (ITRM) Business Model
About Iterum Therapeutics plc
Develops antibiotics for bacterial infections.
Iterum Therapeutics focuses on developing novel antibiotics, particularly targeting drug-resistant pathogens. It generates revenue primarily through the advancement and commercialization of its lead product, sulopenem, which addresses multi-drug resistant Gram-negative infections.
The company is headquartered in Dublin, Ireland, and is positioned in a critical market that requires innovative solutions to combat antibiotic resistance. Its work not only enhances patient care but also influences healthcare policies and practices on a global scale.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
9
CEO
Mr. Corey N. Fishman
Country
Ireland
IPO Year
2018
Website
www.iterumtx.comIterum Therapeutics plc (ITRM) Latest News & Analysis
Iterum Therapeutics plc (NASDAQ: ITRM) will hold its Q4 2024 earnings conference call on February 7, 2025, at 8:30 AM ET, featuring key company executives.
The earnings call provides insights into Iterum Therapeutics' financial performance and strategic direction, influencing investor sentiment and stock valuation.
Iterum Therapeutics' ORLYNVAH TM received FDA approval in Q4 2024. The company is focusing on pre-commercialization and seeking strategic partnerships to address uUTIs. Conference call today at 8:30 am ET.
FDA approval of ORLYNVAH TM enhances Iterum's market position and potential revenue. Extended cash runway supports pre-commercialization efforts, indicating growth prospects for investors.
Iterum Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 7, 2025
1 month agoIterum Therapeutics plc will announce its Q4 and full year 2024 financial results on February 7, 2025, before U.S. market open, followed by a conference call at 8:30 a.m. ET.
Iterum Therapeutics' upcoming financial results and conference call could impact stock performance, reflecting the company's progress in combating drug-resistant infections and overall market confidence.
Iterum Therapeutics Regains Full Nasdaq Compliance
4 months agoIterum will remain listed and traded on the Nasdaq Stock Market, ensuring continued access for investors.
Iterum's continued listing on Nasdaq signals stability, maintaining investor confidence and access to capital, which can positively influence stock performance and investor sentiment.
Iterum Therapeutics plc will hold its Q3 2024 earnings conference call on November 14, 2024, at 8:30 AM ET, featuring key executives and analysts.
Upcoming Q3 earnings call for Iterum Therapeutics on November 14, 2024, will provide insights into financial performance and strategic direction, influencing investor sentiment and stock valuation.
Iterum Therapeutics' ORLYNVAH TM received FDA approval on October 25, 2024. The company will hold a conference call today at 8:30 a.m. EDT to discuss Q3 financial results.
FDA approval of ORLYNVAH TM can boost Iterum Therapeutics' stock by enhancing its product portfolio, potentially increasing revenue from antibiotic sales amid rising antibiotic resistance.
Frequently Asked Questions About ITRM Stock
What is Iterum Therapeutics plc's (ITRM) stock forecast for 2025?
Based on our analysis of 5 Wall Street analysts, Iterum Therapeutics plc (ITRM) has a median price target of $7.50. The highest price target is $10.00 and the lowest is $5.00.
Is ITRM stock a good investment in 2025?
According to current analyst ratings, ITRM has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $1.33. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ITRM stock?
Wall Street analysts predict ITRM stock could reach $7.50 in the next 12 months. This represents a 463.9% increase from the current price of $1.33. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Iterum Therapeutics plc's business model?
Iterum Therapeutics focuses on developing novel antibiotics, particularly targeting drug-resistant pathogens. It generates revenue primarily through the advancement and commercialization of its lead product, sulopenem, which addresses multi-drug resistant Gram-negative infections.
What is the highest forecasted price for ITRM Iterum Therapeutics plc?
The highest price target for ITRM is $10.00 from Gregory Renza at RBC Capital, which represents a 651.9% increase from the current price of $1.33.
What is the lowest forecasted price for ITRM Iterum Therapeutics plc?
The lowest price target for ITRM is $5.00 from Ed Arce at HC Wainwright & Co., which represents a 275.9% increase from the current price of $1.33.
What is the overall ITRM consensus from analysts for Iterum Therapeutics plc?
The overall analyst consensus for ITRM is bullish. Out of 5 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $7.50.
How accurate are ITRM stock price projections?
Stock price projections, including those for Iterum Therapeutics plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
